These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31359471)

  • 1. Letter: clinical outcomes after long-term entecavir or tenofovir treatment in patients with hepatitis D and advanced fibrosis.
    Huang R; Wang J; Wu W; Yan X; Wu C
    Aliment Pharmacol Ther; 2019 Aug; 50(4):471. PubMed ID: 31359471
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B?
    Yuan BH; Zhu YK; Li RH
    Aliment Pharmacol Ther; 2020 Jan; 51(2):314-315. PubMed ID: 31880015
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? Authors' reply.
    Yip TC; Wong GL
    Aliment Pharmacol Ther; 2020 Jan; 51(2):315-316. PubMed ID: 31880016
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
    Köklü S; Tuna Y; Gülşen MT; Demir M; Köksal AŞ; Koçkar MC; Aygün C; Coban S; Ozdil K; Ataseven H; Akin E; Pürnak T; Yüksel I; Ataseven H; Ibiş M; Yildirim B; Nadir I; Küçükazman M; Akbal E; Yüksel O; Başar O; Alkan E; Baykal O
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
    Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
    Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.
    Güzelbulut F; Ovünç AO; Oetinkaya ZA; Senates E; Gökden Y; Saltürk AG; Sezikli M; Ozkara S; Cetinkaya F
    Hepatogastroenterology; 2012; 59(114):477-80. PubMed ID: 21940383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of Histological Response in Chronic Hepatitis B Patients with Tenofovir or Entecavir Therapy].
    Çerçioğlu D; Kınıklı S; Cesur S; Ataman Hatipoğlu Ç; Arslan K; Gönültaş M
    Mikrobiyol Bul; 2020 Jan; 54(1):95-109. PubMed ID: 32050881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis.
    Han Y; Zeng A; Liao H; Liu Y; Chen Y; Ding H
    Int Immunopharmacol; 2017 Jan; 42():168-175. PubMed ID: 27915131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of clinical first-line Antiviral Agents on outcome of chronic hepatitis B treatment].
    Zhao LF; Wang Y
    Zhonghua Gan Zang Bing Za Zhi; 2017 Jul; 25(7):485-489. PubMed ID: 29055984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations.
    Choe WH; Kim K; Lee SY; Choi YM; Kwon SY; Kim JH; Kim BJ
    World J Gastroenterol; 2019 Sep; 25(33):4985-4998. PubMed ID: 31543688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B.
    Ibragimov EK; Abdurakhmanov DT; Rozina TP; Nikulkina EN; Tanaschuk EL; Odintsov AV; Panevkina SV; Moiseev SV
    Ter Arkh; 2019 Mar; 91(2):40-47. PubMed ID: 31094170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    Doğan ÜB; Kara B; Gümürdülü Y; Soylu A; Akin MS
    Turk J Gastroenterol; 2012 Jun; 23(3):247-52. PubMed ID: 22798114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir.
    Ceylan B; Arslan F; Batırel A; Fincancı M; Yardımcı C; Fersan E; Paşaoğlu E; Yılmaz M; Mert A
    Turk J Gastroenterol; 2016 Jan; 27(1):42-6. PubMed ID: 26674977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-To-Head Comparison of Two Years Efficacy of Entecavir and Tenofovir in Patients with Treatment-Naïve Chronic Hepatitis B--The Real Life Data.
    Hepatogastroenterology; 2015 Jun; 62(140):982-6. PubMed ID: 26902041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
    Papatheodoridis GV; Sypsa V; Dalekos G; Yurdaydin C; van Boemmel F; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Loglio A; Siakavellas S; Gatselis N; Keskın O; Lehretz M; Savvidou S; de la Revilla J; Hansen BE; Kourikou A; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2018 Jun; 68(6):1129-1136. PubMed ID: 29427727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients.
    Huang R; Yao R; Wu W; Wang J; Wu C
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1105-1106. PubMed ID: 30920033
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply.
    Chen CH
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1106-1107. PubMed ID: 30920034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.